EUVIMEDEUVIMED entdecken
Crossref

L26/P-404 Hyperbaric oxygen therapy improves ovarian graft survival via Nrf2/HO-1 antioxidant pathway activation

Y. Zhang, Y. He, N. Sun

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von Y. Zhang und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does hyperbaric oxygen therapy protect ovarian grafts from ischemia-reperfusion injury through the Nrf2/HO-1 signaling pathway? Summary answer HBOT significantly improves graft survival by activating Nrf2/HO-1 antioxidant signaling, reducing oxidative stress and apoptosis rather than promoting angiogenesis. What is known already Ovarian tissue transplantation (OTT) is the primary fertility preservation strategy for prepubertal patients, but 60-95% of follicles are lost due to ischemia-reperfusion (I/R) injury. Hyperbaric oxygen therapy (HBOT) improves tissue oxygenation, yet its mechanisms in protecting ovarian grafts remain unclear. The Nrf2/HO-1 pathway is a master regulator of antioxidant defense, but its role in ovarian transplantation is unexplored. This study investigated whether HBOT activates Nrf2/HO-1 signaling to mitigate I/R injury and follicular loss. Study design, size, duration Prospective controlled animal study using a murine autologous ovarian transplantation model. A total of 231 six-week-old female ICR mice were randomly assigned to four groups: Control (sham), OTT (untreated), HBOT-5D (5 days treatment), and HBOT-10D (10 days treatment). Samples were collected at 5, 10, and 21 days post-transplantation. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test. Participants/materials, setting, methods Female ICR mice (6 weeks old) underwent autologous ovarian tissue transplantation under the renal capsule. HBOT was administered at 2.5 ATA for 60 minutes twice daily for 5 or 10 days starting 4 hours post-surgery. Outcomes included estrous cycle recovery, serum hormones (E2, FSH), follicle counts, fibrosis assessment, oxidative stress markers (MDA, SOD), inflammation markers (IL-1β, IL-10), angiogenesis (CD31, HIF-1α), and Nrf2/HO-1 pathway proteins by Western blot. Main results and the role of chance HBOT significantly accelerated estrous cycle recovery (5.67±0.52 vs 6.67±0.52 days, P < 0.05) and restored endocrine function compared to untreated OTT, with elevated estradiol and reduced FSH levels. Histological analysis showed preserved follicular density and reduced stromal fibrosis in HBOT groups. Mechanistically, HBOT downregulated HIF-1α and CD31+ microvessel density, indicating reduced pathological angiogenesis, while upregulating antioxidant enzymes (SOD) and reducing lipid peroxidation (MDA). HBOT also modulated inflammation by decreasing IL-1β and increasing IL-10. Western blot analysis confirmed significant upregulation of Nrf2 and HO-1 proteins, accompanied by reduced apoptotic markers (Bax, cleaved caspase-3) and increased Bcl-2 expression in HBOT-treated mice. No significant differences were observed between 5-day and 10-day treatment regimens. All results were statistically significant (P < 0.05) using ANOVA with appropriate post hoc testing, suggesting the effects are unlikely due to chance. Limitations, reasons for caution This is a preclinical mouse model; translation to human clinical practice requires further validation. The observation period was limited to 21 days, and long-term graft function, pregnancy rates, and offspring health were not assessed. Wider implications of the findings These findings provide a mechanistic basis for optimizing postoperative protocols in fertility preservation. Targeting the Nrf2/HO-1 antioxidant axis represents a novel therapeutic strategy to enhance ovarian graft survival, potentially applicable to other ischemic tissue transplantation scenarios. Trial registration number No

Zitieren

APA

Zhang, Y., He, Y., & Sun, N. (2026). L26/P-404 Hyperbaric oxygen therapy improves ovarian graft survival via Nrf2/HO-1 antioxidant pathway activation. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.738

Vancouver

Zhang Y, He Y, Sun N. L26/P-404 Hyperbaric oxygen therapy improves ovarian graft survival via Nrf2/HO-1 antioxidant pathway activation. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.738

BibTeX
@article{Zhang2026,
  author = {Zhang, Y. and He, Y. and Sun, N.},
  title = {L26/P-404 Hyperbaric oxygen therapy improves ovarian graft survival via Nrf2/HO-1 antioxidant pathway activation},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.738}
}
Kostenlos starten →